JARDIANCE under the microscope: Real-World safety check in korean kidney patients
NCT ID NCT06287073
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This completed study looked at how safe and effective JARDIANCE (empagliflozin) is for Korean adults with chronic kidney disease when used in routine medical care. Researchers tracked 299 patients starting the drug for the first time, recording side effects and changes in a key kidney health marker (urine albumin-creatinine ratio) after 12 and 24 weeks. The goal was to see how the drug performs outside of strict clinical trial conditions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY DISEASE, CHRONIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Chonnam National University Hospital
Gwangju, 61469, South Korea
-
Chungbuk National University Hospital
Cheongiu, 28644, South Korea
-
Hallym University Sacred Heart Hospital
Anyang, 07441, South Korea
-
Inje University Ilsan Paik Hospital
Goyang, 10380, South Korea
-
Korea University Anam Hospital
Seoul, 02841, South Korea
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Soonchunhyang University Hospital Seoul
Seoul, 04401, South Korea
-
The Catholic University of Korea, Eunpyeong St. Mary's Hospital
Seoul, 03312, South Korea
-
The Catholic University of Korea, Yeouido St.Mary's Hospital
Seoul, 07345, South Korea
-
Ulsan University Hospital
Ulsan, 44033, South Korea
-
Yonsei University Wonju Severance Christian Hospital
Gangwon, 26426, South Korea
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Empagliflozin (JARDIANCE)
What this could lead to
If results are positive, this could confirm that JARDIANCE is safe and effective for Korean patients with chronic kidney disease in everyday practice.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to other populations or settings.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.